Imatinib Sandoz (Imatinib)

Imatinib binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, blocking their activity. This inhibition stops downstream signaling pathways that promote cancer cell proliferation and survival, leading to apoptosis of the malignant cells and slowing tumor progression.

The dose of Imatinib Sandoz is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the exact dosing regimen provided by their healthcare professional.

Safety data for imatinib in pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential benefits and risks with their physician before using Imatinib Sandoz.

To place an order, submit an enquiry on the Imatinib Sandoz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer different potency or side‑effect profiles, but Imatinib’s long‑term safety data and cost‑effectiveness make it a widely used reference therapy.

Imatinib Sandoz tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in a bathroom or other humid environment, and keep out of reach of children.

Imatinib Sandoz is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe neutropenia, hepatotoxicity and cardiac failure. Patients should be monitored regularly for blood‑cell counts, liver enzymes and cardiac function. Prompt medical attention is required if symptoms such as fever, jaundice, shortness of breath or swelling develop.

Imatinib Sandoz is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for patients with pre‑existing severe liver disease, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors or inducers without appropriate dose adjustments.